c-Src Increases the Sensitivity to TKIs in the EGFR-Mutant Lung Adenocarcinoma.

c-Src Increases the Sensitivity to TKIs in the EGFR-Mutant Lung Adenocarcinoma.
复制标题

c-Src 增加 EGFR 突变肺腺癌对 TKI 的敏感性

DOI:
10.3389/fonc.2021.602900
复制
发表时间:
2021
影响因子:
4.7
通讯作者:
Zhao Y
Zhao Y
中科院分区:
医学3区
文献类型:
--
作者:
Min W;He C;Zhang S;Zhao Y

文献摘要

参考文献

相似文献

c-Src和表皮生长因子受体(EGFR)是控制细胞对微环境线索的反应的关键顶端激酶。c-Src如何影响EGFR相关信号传导和靶向治疗仍然难以捉摸。最初,caspase-8在酪氨酸380磷酸化的c-Src主要增强c-Src激活,以促进肺腺癌通过获得上皮间质转化(EMT)表型转移。从机制上讲,与其他c-Src伴侣蛋白相比,c-Src SH 2结构域与caspase-8的磷酸酪氨酸380以及SH 3结构域与caspase-8的“PDEP”基序的连接过度激活了c-Src。c-Src不能触发EGFR相关信号。磷酸酪氨酸1068、1086和1145的水平反映了这一点,这些水平对c-Src活化没有影响。酪氨酸激酶抑制剂(TKI)抑制EGFR相关信号传导,通过坏死性凋亡和内源性凋亡导致肺腺癌细胞死亡。鉴于c-Src活化在肺腺癌中很常见,通过达沙替尼阻断c-Src活化可以通过EGFR的SH 2结构域封闭EGFR的生存信号相关磷酸酪氨酸,从而增加TKI在EGFR突变型肺腺癌中的抗肿瘤活性。总之,达沙替尼给药导致c-Src失活可使EGFR突变型肺腺癌对TKI敏感。
c-Src and the epidermal growth factor receptor (EGFR) are key apical kinases that govern cell responses to microenvironmental cues. How c-Src affects EGFR-related signaling and targeted therapy remains elusive. Initially, caspase-8 phosphorylated at tyrosine 380 by c-Src predominantly enhancing c-Src activation to facilitate metastasis through attaining epithelial-mesenchymal transition (EMT) phenotype in lung adenocarcinoma. Mechanistically, the linkage of c-Src SH2 domain with phosphotyrosine 380 of caspase-8 and SH3 domain with “PDEP” motif of caspase-8 overactivates c-Src as compared with other c-Src-partner proteins. c-Src is incapable of triggering EGFR-related signaling. This is reflected by the levels of phosphotyrosine 1068, 1086, and 1145, which have no impact on c-Src activation. Tyrosine kinase inhibitors (TKIs) suppress EGFR-related signaling to yield cell deaths of lung adenocarcinoma by both necroptosis and intrinsic apoptosis. Given that c-Src activation is frequent in lung adenocarcinoma, blocking c-Src activation through dasatinib can seal the survival-signaling-related phosphotyrosines of EGFR by its SH2 domain, which in turn increases the antitumor activity of TKIs in EGFR-mutant lung adenocarcinoma. Collectively, c-Src inactivation by dasatinib administration sensitizes EGFR-mutant lung adenocarcinoma to TKIs.
DOI: 10.7554/elife.14107
发表时间: 2016-03-28
期刊: ELIFE
影响因子: 7.7
作者:
Huang, Yongjian;Bharill, Shashank;Kuriyan, John
通讯作者: Kuriyan, John
DOI: 10.1016/j.celrep.2012.03.010
发表时间: 2012-05-31
期刊: Cell reports
影响因子: 8.8
作者:
Dillon CP;Oberst A;Weinlich R;Janke LJ;Kang TB;Ben-Moshe T;Mak TW;Wallach D;Green DR
通讯作者: Green DR
DOI: 10.1158/0008-5472.can-07-1961
发表时间: 2007-12-15
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Deng, Jing;Shimamura, Takeshi;Letai, Anthony
通讯作者: Letai, Anthony
DOI: 10.1158/0008-5472.can-05-4183
发表时间: 2006-04-15
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Helfer, B;Boswell, BC;Frisch, SM
通讯作者: Frisch, SM
达沙替尼通过 c-Src 磷酸化 caspase-8 促进紫杉醇诱导的肺腺癌坏死性凋亡
DOI: 10.1016/j.canlet.2016.05.003
发表时间: 2016-08-28
期刊: CANCER LETTERS
影响因子: 9.7
作者:
Diao, Yan;Ma, Xiaobin;Zhao, Yang
通讯作者: Zhao, Yang